具有可演变功能的GPCR纳米体连接体的以皮为导向的选择
Meredith A Skiba1, Clare Canavan1, Genevieve R Nemeth1
1Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115.
概括
研究人员开发了一种新方法来创建纳米体,一种抗体片段,可以准G蛋白结合受体 (GPCRs). 这些纳米体显示出开发GPCR新疗法的潜力,例如血管新生素II型I受体 (AT1R).
科学领域:
- 生物技术和制药科学 生物技术和制药科学
- 分子和细胞药理学分子和细胞药理学
- 药物发现和开发 药物发现和开发
背景情况:
- 抗体在向G蛋白结合受体 (GPCRs) 方面具有很高的选择性,这是药物标的关键类别.
- 然而,针对GPCRs的基于抗体的配体的开发仍然有限,阻碍了治疗应用.
研究的目的:
- 开发一种可通用的方法来选择纳米体对抗GPCRs的配体.
- 研究纳米体的潜力,作为调节器和抑制器的血管新生素II型I受体 (AT1R).
主要方法:
- 使用合成驼类抗体碎片 (纳米体) 库来选择GPCR配体.
- 采用结构导向设计,将纳米体全调节器设计成具有竞争力的抑制剂.
- 专注于血管激素II型I受体 (AT1R) 作为模型GPCR点.
主要成果:
- 成功识别了多个纳米体连接体,这些连接体特异于血管新生二型I型受体 (AT1R).
- 证明纳米体可以作为全调节器,表现出受体和连接体化学性质的选择性.
- 通过向突变将两个纳米体转化为具有竞争力的AT1R抑制剂.
结论:
- 纳米体是多功能支架,能够编码针对GPCRs的各种药理行为.
- 开发的选择方法可用于发现新的GPCR向纳米体.
- 工程纳米体对开发下一代GPCR疗法具有重大前景.
相关概念视频
Conservative Site-specific Recombination and Phase Variation
5.9K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
5.9K
GPCR Desensitization
5.7K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.7K


